Breaks Categories: News

TuesdayNov 21, 2023 1:57 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN) Launches Carlsbad-Based CDMO GMP Manufacturing Facility

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced the opening of its new manufacturing facility in Carlsbad, California, to meet the growing demand for its products. The facility will handle orders that SOHM has received and expects to receive in the near future, while its main facility in downtown San Diego undergoes renovation to become fully operational. “I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles…

Continue Reading

TuesdayNov 21, 2023 1:33 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Approval of the Plan of Arrangement with Celly Nu

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that FSD Pharma securityholders (as defined in the announcement) have approved the previously disclosed plan of arrangement under section 182 of the Business Corporations Act (Ontario) pursuant to which common shares in the capital of Celly Nutrition Corp. (“Celly Nu”) will be distributed to the holders of class A multiple voting shares, class B subordinate voting shares, and holders of warrants exercisable for the purchase of class B subordinate voting shares as outlined in the press…

Continue Reading

MondayNov 20, 2023 2:12 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Announces Pricing of $7M Public Offering

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants will be exercisable immediately upon issuance, at an exercise price of $1.30 per share, and will expire five years after the initial exercise date. Subject…

Continue Reading

FridayNov 17, 2023 10:38 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Releases Date for Planned Distribution of Celly Nu Shares

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced the distribution date that its securityholders can expect to receive common shares in the capital of Celly Nutrition Corp. The distribution is subject to the satisfaction of all applicable closing conditions of the arrangement. The arrangement outlines plans for FSD Pharma securityholders to receive one Celly Nu share for each FSD Pharma share or FSD Pharma distribution warrant that they hold. FSD Pharma anticipates that this will result in approximately 45,694,621 Celly Nu shares being distributed…

Continue Reading

FridayNov 17, 2023 10:16 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) News of FDA Type-B Meeting Shared in Syndicated Audio Broadcast

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent NetworkNewsAudio broadcast. According to the broadcast, the company recently announced that it had met with the U.S. Food and Drug Administration (“FDA”) in a Type-B meeting, designed to discuss the positive results from the company’s PAX-HAT-301 study of suramin in stage one human African sleeping sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease. The broadcast was released by via NetworkNewsAudio (“NNA”), a solution that offer companies additional visibility, recognition and brand awareness in the investment community via distribution…

Continue Reading

ThursdayNov 16, 2023 1:08 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Distinct from other anthracyclines, a clinically trusted class of drugs in use for 60 years against dozens of common cancers, and other traditional chemotherapy drugs, CNS…

Continue Reading

ThursdayNov 16, 2023 12:04 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Releases Q3 2023 Financial Report, Corporate Update

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting on its financial results as well as providing a comprehensive business update for the third quarter ended Sept. 30, 2023. Highlights of the report include the successful conclusion of a crucial Type-B meeting with the U.S. Food and Drug Administration designed to gather vital guidance for the NDA submission of PAX-101; the completion of the final PAX-101 phase 3 trials for human African trypanosomiasis (HAT); the strategic acquisition of suramin research assets from Rediscovery Life Sciences (RLS); and the successful completion of a commercial-scale development plan for…

Continue Reading

WednesdayNov 15, 2023 3:47 pm

BioMedNewsBreaks – NextPlat Corp.’s (NASDAQ: NXPL) Strong Growth Featured in Proactive Podcast

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, was featured in an interview with Proactive, where its CEO Charlie Fernandez joined host Steve Darling to provide an update on the company’s latest financial results. NextPlat has made impressive strides in consolidating its global e-commerce and Progressive Care health care operations, leading to significant growth. During the interview, Fernandez highlighted the company’s strong financial performance in the third quarter, reporting consolidated revenues of $15.3 million. This represents a remarkable >481% increase compared to the third quarter of the previous year. In addition, the company’s gross margins saw substantial improvement, reaching 30%…

Continue Reading

WednesdayNov 15, 2023 1:24 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing of Supplement to Management Information Circular

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed a supplement related to certain restrictions on resale that will apply to the Celly Nu shares that will be distributed to the FSD Pharma securityholders. The company filed the supplement, dated Nov. 15, 2023, as an addition to the Management Information Circular that was filed last month; the company noted that capitalized terms not defined in this news release have the meanings assigned in the circular. The supplement was filed in connection with the company’s upcoming…

Continue Reading

WednesdayNov 15, 2023 1:05 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, 2023; the company also noted upcoming milestones. Notable financial numbers from the report include net loss for Q3 totaled approximately $4.5 million compared to an estimated $3.4 million for the comparable period in 2022; R&D expenses came in at $3.4 million for the third quarter compared to approximately $2.2 million for the comparable period in 2022; and general and administrative…

Continue Reading